Accéder au contenu
Merck
  • Adverse reactions of Achilles tendon xanthomas in three hypercholesterolemic patients after treatment intensification with niacin and bile acid sequestrants.

Adverse reactions of Achilles tendon xanthomas in three hypercholesterolemic patients after treatment intensification with niacin and bile acid sequestrants.

Journal of clinical lipidology (2013-02-19)
Wanda C Lakey, Nicole Greyshock, John R Guyton
RÉSUMÉ

Multiple cholesterol-reducing therapies have been shown to induce the regression of tendon xanthoma in patients with familial hypercholesterolemia. We present 3 cases of adverse reactions in Achilles tendon xanthomas after the addition of niacin and bile acid sequestrants to ongoing statin therapy. Reduction in tendon dimensions and marked softening of xanthomas were interpreted as cholesterol removal from heavily infiltrated tissue sites. In 2 cases, changes in the xanthomas occurred despite only minor lipoprotein improvements, raising the possibility of direct drug effects in cholesterol-infiltrated tissue. Intriguingly, recent studies have described niacin receptor-mediated effects in macrophages. In summary, although adverse reactions in Achilles tendon xanthomas appear to be infrequent, clinicians should be aware of this phenomenon in their patients after intensifying lipid treatments, especially with the use of niacin in patients with familial hypercholesterolemia. Xanthoma responses may provide clues to new pharmacologic effects in cholesterol-infiltrated tissues.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Acide nicotinique, ≥99.5% (HPLC)
Sigma-Aldrich
Acide nicotinique, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, ≥98%
Supelco
Acide nicotinique, analytical standard
Sigma-Aldrich
Acide nicotinique, ≥98%
Supelco
Acide nicotinique, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Nicotinic acid sodium salt, 98%
Sigma-Aldrich
Acide nicotinique, meets USP testing specifications